Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 2×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Cited by
Items 201–300 of 371
Lymph microvascularization as a prognostic indicator in neuroblastoma
Tadeo, I., Gamero‐Sandemetrio, E., Berbegall, A. P., Gironella-Torrent, M., Ritort, F., Cañete, A., Bueno, G., Navarro, S., & Noguera, R. (2018) · Oncotarget · doi:10.18632/oncotarget.25457 · Cited by 14
“This normalized tumor vasculature becomes less permeable and tortuous and leads to reduced fluid extravasation within the interstitium, resulting in a decrease in tumor interstitial fluid pressure [54, 55].”
BackgroundHa, H.-J., Choi, Y., Kim, N.-H., Kim, J., Jang, J., Niepa, T. H. R., Tanaka, M., Lee, H.-Y., & Choi, J. H. (2025) · Biomaterials Research · doi:10.34133/bmr.0144 · Cited by 15
“Despite its potential, vascular normalization still faces obstacles, including its limited duration of effectiveness and inadequate delivery of oxygen and drugs to the tumor [ 20 , 49 , 50 ].”
Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells
Li, Y., Liu, X., Dong, Y., & Zhou, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189323 · Cited by 17
Guo, Y. G., Xia, P., Zheng, J., Sun, X., Pan, X., Zhang, X., & Wu, C. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.06.006 · Cited by 13
Yuan, H., Zhang, J.-P., Kong, W., Liu, Y., Lin, Z., Wang, W., & Guo, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2602-9 · Cited by 13
“The vascular endothelial growth factor (VEGF) system plays an important role in regulating the process of angiogenesis, and the clinical benefit from targeting this system in patients with metastatic renal cell carcinoma (mRCC) is well documented [4, 5].”
BackgroundTalati, P., El-Abtah, M. E., Kim, D., Dietrich, J., Fu, M., Wenke, M. R., He, J., Natheir, S. N., Vangel, M. G., Rapalino, O., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab060 · Cited by 12
Taguchi, E., Horiuchi, K., Senoo, A., Susa, M., Inoue, M., Ishizaka, T., Rikitake, H., Matsuhashi, Y., & Chiba, K. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.033 · Cited by 12
Kuznetsov, M. B. (2020) · Mathematics · doi:10.3390/math8050760 · Cited by 12
Role of vascular endothelium and exosomes in cancer progression and therapy (Review)
Dai, Y., Yao, Y., He, Y., & Hu, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5712 · Cited by 11
“This induces a stronger hypoxic response and tumor aggressiveness, which ultimately leads to drug resistance and even cancer metastasis (54).”
The role of nitric oxide in inflammation, tumor microenvironment, and cancer therapy
Nair, A., Madhyastha, H., Revanasiddappa, B. C., Pai, V., Kumar, D., Neenu, M. K., & Prabhu, P. P. (2026) · Nitric Oxide · doi:10.1016/j.niox.2026.02.005 · Cited by 18
Boer, J. C., Walenkamp, A., & den Dunnen, W. F. A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.001 · Cited by 12
“anti-angiogenic drugs should contain compounds targeting the BMDC recruitment Here we discuss the theoretical feasibility of anti-VEGF treatment in combination with targeted agents directed against Ang/Tie-2 axis, CXCR4, PlGF or PDGF-B”
BackgroundTargeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer
Zhu, J., Wang, L., Liu, F., Pan, J., Yao, Z., Lin, Y., Yang, Y., Xiong, X., Li, K., Yang, Y., et al. (2022) · Cancers · doi:10.3390/cancers14020383 · Cited by 12
Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
Orr, B. A., & Eberhart, C. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1641 · Cited by 11
“Other targets such as the Angiopoetin–Tie2 axis, placental growth factor (PlGF), and the Notch pathway are also increasingly being studied (53).”
BackgroundNagaraja, T. N., Elmghirbi, R., Brown, S. L., Rey, J. A., Schultz, L. R., Mukherjee, A., Cabral, G., Panda, S., Lee, I. Y., Sarntinoranont, M., et al. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4516 · Cited by 11
Sun, W., Dion, E., Laredo, F., Okonak, A., Sepeda, J. A., Haykal, E., Zhou, M., El‐Hodiri, H. M., Fischer, A. J., Silver, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.020 · Cited by 10
“81 Whether normalization of pro-and antiangiogenic signaling may be required to promote the formation of structurally sound and functionally normal vasculature networks after SCI remains to be tested.”
Carmona‐Rodríguez, L., Martínez-Rey, D., Martín-González, P., Franch, M., Sorokin, L. M., Mira, E., & Mañes, S. (2022) · Cancers · doi:10.3390/cancers14051226 · Cited by 11
Ciocâlteu, A., Săftoiu, A., Cârţână, T., Gruionu, L. G., Pirici, D. N., Georgescu, C. C., Georgescu, C.-V., Gheonea, D. I., & Gruionu, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091084 · Cited by 10
Sharan, S., & Woo, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.36 · Cited by 10
Kouhsoltani, M., Khiavi, M. M., Jamali, G., & Farnia, S. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.086 · Cited by 10
Hadjicharalambous, M., Ioannou, E., Aristokleous, N., Gazeli, K., Anastassiou, C., & Vavourakis, V. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111246 · Cited by 10
Tumour suppressor PTEN activity is differentially inducible by myo‐inositol phosphates
Grzymajło, K., Hafny‐Rahbi, B. E., & Kiéda, C. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17699 · Cited by 10
The Effect of Stem Cells and Vascular Endothelial Growth Factor on Cancer Angiogenesis
Moradi-Gharibvand, N., & Hashemibeni, B. (2023) · Advanced Biomedical Research · doi:10.4103/abr.abr_378_21 · Cited by 12
“[5] Interaction and balance between pro‐angiogenic and anti‐angiogenic factors regulate angiogenesis[26] [Figure 1].”
BackgroundChen, Y., Di, M., Tang, Y., Zhao, J., Wang, Q., Guo, Z., Li, Y., Ouyang, D., Yang, J., Chen, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03061-w · Cited by 9
“Taken together, our results demonstrate that EBV infection upregulates the expression of ANXA3, a key regulatory molecule involved in vascular abnormalities caused by EBV infection, through EBNA1.”
Bajger, P., Bodzioch, M., & Foryś, U. (2020) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.6958 · Cited by 9
“Note that, under conditions (6)–(7), the following inequalities hold:”
BackgroundPitman, K. E., Bakke, K. M., Kristian, A., & Malinen, E. (2019) · Cancer Imaging · doi:10.1186/s40644-019-0280-y · Cited by 8
Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?
Sun, X., Nosrati, Z., Ko, J., Lee, C.-M., Bennewith, K. L., & Bally, M. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082022 · Cited by 8
“This TVN effect is normally accompanied by a significant reduction in pro-angiogenic and anti-inflammatory factors [64,65].”
BackgroundFleischer, T., Haugen, M. H., Ankill, J., Silwal‐Pandit, L., Børresen‐Dale, A., Hedenfalk, I. A., Hatschek, T., Tost, J., Engebraaten, O., & Kristensen, V. N. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13656 · Cited by 8
“With the rationale of denying tumors access to nutrients and oxygen through vascular endothelial growth, anti-angiogenic therapy has been applied to decrease tumor size in the neoadjuvant setting [1 – 3].”
Sweeney, A., Langley, A., Xavierselvan, M., Shethia, R. T., Solomon, P., Arora, A., & Mallidi, S. (2025) · Theranostics · doi:10.7150/thno.99361 · Cited by 10
“All of these observed changes are consistent with previous reports of vascular normalization [17, 23, 24, 51, 120], which we go on to histologically validate in further sections.”
InfluentialDendrimer-mediated targeting of angiogenic biomarkers: therapeutic intervention against cancer
Pathak, A., Jain, N. K., & Jain, K. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2394631 · Cited by 8
“Therefore, anti-VEGF therapy improve the activity of chemotherapeutic agents by normalization of blood vessels [45].”
Chen, D., Lin, C., & WANG, Y.-F. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2586 · Cited by 9
“The closure of the window may be a result of excessively high or prolonged dosing of anti-VEGF treatment (16).”
Tobin, N. P., Wennmalm, K., Lindström, L. S., Foukakis, T., He, L., Genové, G., Östman, A., Landberg, G., Betsholtz, C., & Bergh, J. C. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1691 · Cited by 8
“These results are in line with the concept of vascular normalization following treatment with an angiogenic inhibitor (34,35), but notably, are the first demonstration of this principle on a transcriptional level in human breast tumor samples.”
ResultPericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis
He, Q., Li, X., He, L., Li, Y., Betsholtz, C., & Welsh, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33110 · Cited by 9
“VEGFA is a major player in this context(2) and tumor overproduction of this factor may cause leaky vessels with poor pericyte coverage.(39) The present study demonstrates that poor pericyte coverage due to cell autonomous effects in this cell type by itself causes increased leakiness and metastasis.”
BackgroundInfluentialMorotti, M., Dass, P. H., Harris, A. L., & Lord, S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0442-x · Cited by 8
Junker, P., Puppe, J., Thangarajah, F., Domröse, C. M., Cepic, A., Morgenstern, B., Ratiu, D., Hellmich, M., Mallmann, P. K., & Wirtz, M. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0641-5588 · Cited by 8
Recurrent Low-Dose Chemotherapy to Inhibit and Oxygenate Head and Neck Tumors
Khan, N. I., Hou, H. G., Hodge, S., Kuppusamy, M. L., Chen, E. Y., Eastman, A. R., Kuppusamy, P., & Swartz, H. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0620-8_14 · Cited by 8
“Several pre-clinical studies have now confirmed a persistent anti-angiogenic effect using recurrent low-dose schedules, which led to the concept of vascular normalization [2, 3].”
BackgroundHypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers
Alenezi, A., Alhamad, H., Alenezi, A., & Khan, M. U. H. (2025) · Pharmaceuticals · doi:10.3390/ph18040459 · Cited by 7
Benefits and Pitfalls of Tumor Vessel Normalization
Park, J., Park, I., & Koh, G. Y. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_46 · Cited by 7
Lung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors
Sharma, K., Saini, K., Chimaniya, P., Sahu, S., Gantayat, D., Sharma, R., Bhatt, S., & Shilpi, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_15 · Cited by 7
Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations
Rego, G. N. A., Alves, A. H., Nucci, M. P., Mamani, J. B., Oliveira, F. A., & Gamarra, L. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124490 · Cited by 8
Nagaraja, T. N., & Lee, I. Y. (2021) · Microcirculation · doi:10.1111/micc.12679 · Cited by 7
Welsh, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042313 · Cited by 8
“Anti-angiogenic treatment will reverse many of these vascular abnormalities and that process has been given the name “vascular normalization” [22].”
BackgroundLobo, M. R., Kukino, A., Tran, H. T. D., Schabel, M. C., SPRINGER, C. S. J., Gillespie, G. Y., Grafe, M. R., Woltjer, R. L., & Pike, M. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144488 · Cited by 6
“[10, 12, 64, 65] While preclinical and clinical evidence for this effect has accumulated, its extent and the time window over which it occurs is highly variable and model dependent, with a notably short time window in orthotopic rodent models.[10, 64, 65] Improved vascular efficiency is not synonymous with increased b…”
BackgroundPazos, M. C., Sequeira, G. R., Bocchicchio, S., May, M., Abramovich, D., Parborell, F., Tesone, M., & Irusta, G. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26404 · Cited by 7
Righi, M., Locatelli, S. L., Carlo‐Stella, C., Presta, M., & Giacomini, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35788-4 · Cited by 6
Prebble, A. R., Weishaar, K. M., Thamm, D. H., Leary, D. M., LaRue, S. Μ., Martin, T. W., & Boss, M. (2021) · Veterinary and Comparative Oncology · doi:10.1111/vco.12756 · Cited by 6
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Fu, Y., Zhang, Y., Hu, D., Zhou, Z., Xu, L., & Chen, M. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02615 · Cited by 8
Eguchi, S., Luo, W., Zhu, H., Rosenblum, J., Cooper, A. R., & Cairo, M. S. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201061 · Cited by 7
“95 Although this increased blood supply might seem to risk fueling tumor growth by providing more oxygen and nutrients, evidence suggests that, when carefully timed and combined with therapies like immunotherapy or chemotherapy, vascular normalization can shift the TME in a way that suppresses…”
Cancer Reversion Therapy: Prospects, Progress and Future Directions
Oisakede, E. O., Olawade, D. B., Bello, O. J., Analikwu, C. C., Egbon, E., Fapohunda, O., & Boussios, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121049 · Cited by 6
Tulsian, K., Thakker, D., & Vyas, V. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141364 · Cited by 6
Li, W., Zhang, Y.-R., Zhu, H.-J., Su, N., Sun, R.-X., Mao, X., Yang, Q., & Yuan, S. (2025) · JCI Insight · doi:10.1172/jci.insight.187836 · Cited by 9
“Antiangiogenic therapy enhances vascular normalization by restoring equilibrium between pro-and antiangiogenic signaling, leading to a vasculature with improved architecture and function (6, 7).”
Büning, H., & Hacker, U. T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_12 · Cited by 5
Kontos, C. D., & Willett, C. G. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt199 · Cited by 6
Tadeo, I., Álvaro, T., Navarro, S., & Noguera, R. (2016) · InTech eBooks · doi:10.5772/62479 · Cited by 6
“This normalized tumor vasculature becomes less permeable and tortuous and leads to reduced fluid and protein extravasation into the interstitium, resulting in the decrease tumor interstitial pressure [129, 130].”
BackgroundWang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W. Y., Sun, S., & Lu, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10354 · Cited by 5
“Previously, thalidomide has been reported to increase the radiotherapy sensitivity of EC cells (30).”
BackgroundAntibody therapeutics for epithelial ovarian cancer
Ruiz, M., Zhang, N., Sood, A. K., & An, Z. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2141565 · Cited by 6
“According to preclinical and clinical studies, antiangiogenic therapies, such as bevacizumab, work to restore the balance between pro- and anti-angiogenic signaling, allowing for the normalization of blood vessel structure and function, which has been deemed the ‘vascular normalization’ hypothesis [121].”
BackgroundThe Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis
Ruff, S. M., Shannon, A. H., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15133513 · Cited by 6
“This process causes the regression of existing tumor vasculature, decreases the development of new vessels to prevent tumor growth, and normalizes tumor vasculature to improve chemotherapy delivery [39,40].”
BackgroundZhang, Y., Zhang, K., Xu, L., Lu, X., Hu, P., Long, J., Cui, N., Wu, X., Ye, Y., Xu, G., et al. (2025) · Small · doi:10.1002/smll.202409664 · Cited by 4
Zhang, X., Wang, Y., Xie, M., Corbett, C. J., Singhal, S. K., Dai, B., Wang, J., Ding, Q., Lu, Q., & Wang, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00628 · Cited by 4
Cancer Biology and the Principles of Targeted Cancer Drug Discovery
Hillmann, P., Schmitz, D., Mestan, J., D'Allonzo, S., & Fabbro, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12390-x · Cited by 5
The road ahead for applications of mechanics in drug delivery
Sarmadi, M., Krishnan, S. R., Ramadi, K. B., & Langer, R. (2022) · Mechanics Research Communications · doi:10.1016/j.mechrescom.2022.103956 · Cited by 5
Tisza, A., Klikovits, T., Benej, M., Török, S., Szeitz, B., Valkó, Z., Hoda, M. A., Hegedűs, B., Bonta, M., Nischkauer, W., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15813 · Cited by 4
New Treatment Modalities for the Management of Peritoneal Metastases
Bhatt, A., & Mehta, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-7053-2_20 · Cited by 4
Mazzaschi, G., Olivari, A., Pavarani, A., Lagrasta, C. A. M., Frati, C., Madeddu, D., Lorusso, B., Dallasta, S., Tommasi, C., Musolino, A., et al. (2022) · Cancers · doi:10.3390/cancers14133249 · Cited by 5
“This process mainly consists of restoration of pericyte coverage, improved vessel perfusion/permeability, ultimately leading to attenuated hypoxia [66,67].”
BackgroundGielata, M., Karpińska, K., Gwiazdowska, A., Boryń, Ł. M., & Kobielak, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-16802-2 · Cited by 5
Introduction to monoclonal antibodies.
Mach, J. (2012) · Europe PMC (PubMed Central) · Cited by 5
Cichoń, T., Jarosz–Biej, M., Smolarczyk, R., Ogórek, B., Matuszczak, S., Wagner, M., Mitrus, I., Sochanik, A., Jazowiecka-Rakus, J., & Szala, S. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2125 · Cited by 4
“(2004) improved functioning of tumor vasculature, the so-called normalization of tumor blood vessels, may substantially affect accessibility of drugs to cancer cells (Tong et al., 2004; Goel et al., 2012).”
BackgroundInfluentialAntiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors
Wu, T., & Lin, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.012 · Cited by 4
Pelz, K. R., Gribbin, K. P., Sevetson, T., & Brody, J. R. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2557414 · Cited by 5
“66 HuR target cyclooxegenase-2 (COX-2), an inducible isoform of the cyclooxygenase enzyme involved in prostaglandin biosynthesis, is also upregulated in tumor-associated ECs and HuR has been reported to bind and stabilize its mRNA in vitro (Table 1).”
Quantification of the tumour microvascular response to high dose-per-fraction radiotherapy
Zabel, W. J., Contreras-Sánchez, H. A., Allam, N., Qureshi, M. M., Flueraru, C., Taylor, E., & Vitkin, I. A. (2025) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ade048 · Cited by 3
“…blockades, often at sub-therapeutic dose levels, could induce a more normal vascular structure (by disabling the most dysfunctional regions of the abnormal tumour vascularity) and lead to increased tumour perfusion and thus enhanced treatment response for subsequent therapies (Goel et al 2012).”
Microenvironmental Induced Essentiality of Autophagy
Singleton, D. C., & Harris, A. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0634 · Cited by 3
“In some cases, the beneficial effects of bevacizumab maybe due to vascular normalization, resulting in improved drug delivery and radiation sensitivity (3).”
BackgroundMurgai, M., Thomas, J. A., Cherepanova, O., Delviks‐Frankenberry, K. A., Deeble, P. D., Pathak, V. K., Rekosh, D. M., & Owens, G. K. (2013) · Retrovirology · doi:10.1186/1742-4690-10-34 · Cited by 3
“impaired delivery of chemotherapeutic agents, resulting in higher levels of agents in normal versus tumor tissues [21], which is also thought to contribute to the poor overall efficacy of anti-angiogenic therapies due to counteracting effects of combined therapies.”
Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma
Zheng, T., Jiang, H., Wei, Y., Huang, Z., Chen, J., Duan, T., & Song, B. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.03.10 · Cited by 3
Normalization of the tumor vasculature
Klein, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816196-8.00015-1 · Cited by 3
α-SMA positive vascular mural cells suppress cyst formation in hemangioblastoma
Sakaguchi, M., Nakajima, R., Ichinose, T., Tanaka, S., Kimura, R., Sabit, H., Nakada, S., & Nakada, M. (2023) · Brain Tumor Pathology · doi:10.1007/s10014-023-00465-6 · Cited by 3
“The vascular normalization concept takes advantage of pericytes by only eliminating vessels not covered by pericytes, leaving pericytes covered by functional vasculature [30].”
BackgroundZhang, Y., Numata, K., Imajo, K., Uojima, H., Funaoka, A., Komiyama, S., Ogushi, K., Chuma, M., Irie, K., Kokubu, S., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14089 · Cited by 3
“45 Additionally, antiangiogenic therapies may normalize tumor blood vessels, 46–48 potentially enhancing drug delivery 22,23,47–49 and immune infiltration and interferon response through reconstructing the TME.”
Baek, S., Noh, K., Zhao, Y., Schoemig-Markiefka, B., Ratiu, D., Domröse, C. M., Mallmann, M. R., Mallmann, P., & Pilch, H. (2024) · In Vivo · doi:10.21873/invivo.13791 · Cited by 3
“Bevacizumab is a recombinant human monoclonal VEGF antibody, which inhibits angiogenesis of the tumor through competitive inhibition of VEGF receptors (16, 17).”
BackgroundOBSOLETE: Computational Systems Biology for the VEGF Family in Angiogenesis
Imoukhuede, P. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99548-5 · Cited by 3
Peng, J., Xu, H., Chen, Y., Wang, W., Zhu, L., Shao, Y., & Wang, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.095 · Cited by 3
In Vivo Imaging and Quantitation of the Host Angiogenic Response in Zebrafish Tumor Xenografts
Britto, D. D., Hall, C. J., & Astin, J. W. (2019) · Journal of Visualized Experiments · doi:10.3791/59849 · Cited by 3
The lethal symbiont: exploring the pathophysiology of cancer
Nolan, E., Li, L., Giampazolias, E., Ombrato, L., & Malanchi, I. (2026) · Physiological Reviews · doi:10.1152/physrev.00019.2025 · Cited by 2
Role of Angiogenesis in Oncology: A Deep Insight into the Mechanistic Aspect
(2024) · Letters in Applied NanoBioScience · doi:10.33263/lianbs134.161 · Cited by 2
Radiation Induces Pericyte-Myofibroblast Transition
Yamazaki, T., Jordan, K. R., Fox, N., & Young, K. H. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.05.083 · Cited by 3
Angiogenese beim malignen Melanom
Felcht, M., & Thomas, M. (2015) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12580_suppl · Cited by 6
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Ding, L., & Finley, S. D. (2021) · Computational and Systems Oncology · doi:10.1002/cso2.1013 · Cited by 3
Wang, L. S., Liu, Z., Liang, Y., Wang, J., & Yu, J. (2025) · Preprints.org · doi:10.20944/preprints202507.2175.v1 · Cited by 1
Tang, X., Chen, J., Zhao, Z., Liu, J., Yu, R., Zhao, K., Wang, F., Li, Y., Tian, B., Yuan, D., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00869 · Cited by 1
Wang, Z., Ren, B., Yang, H., Qiu, X., Wu, Y., Xue, C., Zhao, Y., Li, X., Yu, Z. Y., & Zhang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446950 · Cited by 1
Monitoring Pharmacological Treatment of Breast Cancer with MRI
Mytych, W., Czarnecka–Czapczyńska, M., Bartusik‐Aebisher, D., Aebisher, D., & Kawczyk‐Krupka, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100807 · Cited by 2
“In addition, treatments that lead to cell destruction enlarge the extracellular space, which can temporarily increase contrast uptake in the late stage [43,44].”
He, L., Testini, C., Hekmati, N., Bonello, A., Schiza, A., Nwadozi, E., Phillipson, M., Strell, C., & Welsh, M. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70144 · Cited by 1
“However, as a result, the tumor vasculature is commonly dysfunctional and leaky [10 – 12], and these characteristics play a role in tumor cell intravasation, hemato-genic dissemination, and metastasis [13].”
Advanced strategies to improve the accumulation of nanotherapeutics in tumor
Choudhury, S., Tamang, R., Singh, V., Saad, M., Yadav, P., & Talegaonkar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00012-0 · Cited by 1
Liang, C., Wang, M., Li, T., Duan, Y., Song, C., & Yao, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03584-4 · Cited by 3
“However, the clinical efficacy of these drugs is still not satisfactory [33].”
Yamamoto, Y., Teshigawara, A., Tamura, R., Takei, J., Morimoto, Y., Tomoto, K., Akasaki, Y., Hasegawa, Y., Murayama, Y., Miyake, K., et al. (2026) · Cancers · doi:10.3390/cancers18030488 · Cited by 1
“Within the conceptual framework of vascular normalization, anti-VEGF therapy is thought to transiently restore a more organized and functional microvasculature, thereby improving oxygenation and drug delivery while reducing edema [24,26,27].”
Gecko protein F2 inhibits tumor angiogenesis by suppressing the VEGF/MAPK/ERK signaling pathway
Jiang, H., Wang, H., Wei, X., Xie, X., Li, R., Sun, Y., & Wang, C. (2026) · Medical Oncology · doi:10.1007/s12032-026-03265-y · Cited by 1
“The “vascular normalization” concept [ 52 ] in oncology posits that block - ing the VEGF/VEGFR pathway transiently improves tumor vascular architecture and perfusion, which in turn facilitates cytotoxic T cell entry into the tumor core.”
Marcos-Zazo, L., Carrera-Aguado, I., Gómez-Escudero, J., Berlana-Galán, P., Torre-Cea, I., Guerra-Paes, E., Redondo-Gonzalez, C., Sánchez-Mateos, J., Cáceres-Calle, D., Maiques, Ó., et al. (2026) · Angiogenesis · doi:10.1007/s10456-026-10085-1 · Cited by 1
“Vascular normalization is a therapeutic strategy that induces a transition from a chaotic and dysfunctional vascular network into a structurally and functionally normal vasculature, thereby enhancing treatment efficacy across a variety of diseases [ 20 ].”
Tumor vascular conundrum: Hypoxia, ceramide, and biomechanical targeting of tumor vasculature
Kaffas, A. E., & Czarnota, G. J. (2016) · CRC Press eBooks · doi:10.1201/b19690-3 · Cited by 1
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_10 · Cited by 2
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_10-1 · Cited by 1
The BMP910-ALK1-Endoglin Pathway as a Target of Anti-Angiogenic Therapy in Cancer
Tabosh, T. A., Tarrass, M. A., & Bailly, S. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/imcac.1.2021.21 · Cited by 2
Büning, H., & Hacker, U. T. (2015) · Springer eBooks · doi:10.1007/978-3-319-22473-2_12 · Cited by 1
The Role of Platelets in the Tumor Microenvironment
Guo, Q., Roweth, H. G., Johnson, K. E., McAllister, S. S., Italiano, J. E., & Battinelli, E. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_15 · Cited by 3
Metadata
- Authors
- Goel, S., Wong, A. H.-K., & Jain, R. K.
- Affiliations
- Harvard University (US)
- ORCID
- Goel, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-18
- Volume
- 2
- Issue
- 3
- Pages
- a006486-a006486
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282493
- OpenAlex
- W2115852392
- Cited by
- 352
- References
- 191
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 22 · 2023: 27 · 2022: 18 · 2021: 31 · 2020: 30 · 2019: 23 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 28 · 2014: 21 · 2013: 13 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- US-UK Fulbright Commission
- Fulbright Australia
- National Institutes of Health (W81XWH, CA126642, CA115767, R01-CA85140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, R01 CA 85140, R01CA085140, P01CA080124, R01CA126642, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, pathological angiogenesis, anti-angiogenic therapy, tumor vasculature, tumor microenvironment, solid tumors
- MeSH terms
- Cytotoxins, Humans, Macular Degeneration, Neoplasms, Neuroma, Acoustic, Psoriasis, Telangiectasia, Hereditary Hemorrhagic, Disease Progression, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Microvessels, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.